Spyre Therapeutics, Inc. (SYRE)
NASDAQ: SYRE · Real-Time Price · USD
63.27
+11.98 (23.36%)
At close: Apr 13, 2026, 4:00 PM EDT
62.29
-0.98 (-1.55%)
After-hours: Apr 13, 2026, 7:57 PM EDT
Spyre Therapeutics Employees
Spyre Therapeutics had 102 employees as of December 31, 2025. The number of employees increased by 37 or 56.92% compared to the previous year.
Employees
102
Change
37
Growth
56.92%
Revenue / Employee
n/a
Profits / Employee
-$1,240,608
Market Cap
4.97B
Employees Chart
Employees History
| Date | Employees | Change (1Y) | Growth (1Y) |
|---|---|---|---|
| Dec 31, 2025 | 102 | 37 | 56.92% |
| Sep 30, 2025 | 95 | 35 | 58.33% |
| Jun 30, 2025 | 87 | 27 | 45.00% |
| Mar 31, 2025 | 73 | 43 | 143.33% |
| Dec 31, 2024 | 65 | 35 | 116.67% |
| Sep 30, 2024 | 60 | 46 | 328.57% |
| Dec 31, 2023 | 30 | -39 | -56.52% |
| Jun 30, 2023 | 14 | -78 | -84.78% |
| Mar 31, 2023 | 61 | -38 | -38.38% |
| Dec 31, 2022 | 69 | -32 | -31.68% |
| Sep 30, 2022 | 69 | -21 | -23.33% |
| Jun 30, 2022 | 92 | 1 | 1.10% |
| Mar 31, 2022 | 99 | 11 | 12.50% |
| Dec 31, 2021 | 101 | 11 | 12.22% |
| Sep 30, 2021 | 90 | 3 | 3.45% |
| Jun 30, 2021 | 91 | 8 | 9.64% |
| Mar 31, 2021 | 88 | 9 | 11.39% |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Sep 30, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Jun 30, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Sep 30, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Jun 30, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Sep 30, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Jun 30, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Sep 30, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Jun 30, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Sep 30, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Jun 30, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
| Company Name | Employees |
|---|---|
| Caris Life Sciences | 1,846 |
| Apellis Pharmaceuticals | 739 |
| Corcept Therapeutics | 730 |
| Amicus Therapeutics | 511 |
| TG Therapeutics | 399 |
| CRISPR Therapeutics AG | 393 |
| Xenon Pharmaceuticals | 370 |
| Immunovant | 362 |
SYRE News
- 10 hours ago - Spyre Therapeutics Announces Proposed Public Offering of its Common Stock - GlobeNewsWire
- 13 hours ago - Spyre Therapeutics Breaks Higher On Positive Data From Ulcerative Colitis Drug - Benzinga
- 20 hours ago - Spyre Announces Potential Best-in-Class SPY001 Part A Induction Results from SKYLINE Trial in Moderate-to-Severe Ulcerative Colitis Patients - GlobeNewsWire
- 3 days ago - Spyre Therapeutics to Host Conference Call to Report SPY001 Part A Induction Topline Results from SKYLINE Trial in Moderate-to-Severe Ulcerative Colitis Patients on April 13, 2026 - GlobeNewsWire
- 10 days ago - Spyre Therapeutics Announces Grants of Inducement Awards - GlobeNewsWire
- 6 weeks ago - Spyre Therapeutics to Participate in Upcoming March Investor Conferences - GlobeNewsWire
- 7 weeks ago - Spyre Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Corporate Update - GlobeNewsWire
- 3 months ago - Spyre Therapeutics Poised for Transformational 2026 With Six Expected Proof-of-Concept Readouts Beginning in Q2 - GlobeNewsWire